Evaluations of cardiovascular diseases with hybrid PET-CT imaging

Author(s):  
Antti Saraste ◽  
Sami Kajander ◽  
Juhani Knuuti
2020 ◽  
Vol 21 (12) ◽  
pp. 1320-1330
Author(s):  
Riemer H J A Slart ◽  
Andor W J M Glaudemans ◽  
Olivier Gheysens ◽  
Mark Lubberink ◽  
Tanja Kero ◽  
...  

Abstract With this summarized document we share the standard for positron emission tomography (PET)/(diagnostic)computed tomography (CT) imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is) as recently published in the European Journal of Nuclear Medicine and Molecular Imaging. This standard should be applied in clinical practice and integrated in clinical (multicentre) trials for optimal standardization of the procedurals and interpretations. A major focus is put on procedures using [18F]-2-fluoro-2-deoxyglucose ([18F]FDG), but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this summarized document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicentre trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Diagnosis and management of 4Is related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/magnetic resonance, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications.


Author(s):  
Riemer H. J. A. Slart ◽  
◽  
Andor W. J. M. Glaudemans ◽  
Olivier Gheysens ◽  
Mark Lubberink ◽  
...  

Abstract With this document, we provide a standard for PET/(diagnostic) CT imaging procedures in cardiovascular diseases that are inflammatory, infective, infiltrative, or associated with dysfunctional innervation (4Is). This standard should be applied in clinical practice and integrated in clinical (multicenter) trials for optimal procedural standardization. A major focus is put on procedures using [18F]FDG, but 4Is PET radiopharmaceuticals beyond [18F]FDG are also described in this document. Whilst these novel tracers are currently mainly applied in early clinical trials, some multicenter trials are underway and we foresee in the near future their use in clinical care and inclusion in the clinical guidelines. Finally, PET/MR applications in 4Is cardiovascular diseases are also briefly described. Diagnosis and management of 4Is-related cardiovascular diseases are generally complex and often require a multidisciplinary approach by a team of experts. The new standards described herein should be applied when using PET/CT and PET/MR, within a multimodality imaging framework both in clinical practice and in clinical trials for 4Is cardiovascular indications.


2005 ◽  
Vol 44 (S 01) ◽  
pp. S58-S60 ◽  
Author(s):  
W. Mohnike

Summary:PET is being considered a diagnostic commodity in clinical practice worldwide and thus receives increasing attention by health insurances and governmental organizations. In Germany, however, neither PET nor PET/CT are subject to reimbursement. This renders clinical PET and PET/CT imaging a challenge both in a general hospital environment and in private practice. This article describes briefly these challenges, which are not solely related to turf battles and associated costs.


2019 ◽  
Author(s):  
W van Boxtel ◽  
S Lütje ◽  
AC van Engen-van Grunsven ◽  
GW Verhaegh ◽  
JA Schalken ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2145-P
Author(s):  
ELIZABETH SANCHEZ RANGEL ◽  
JASON BINI ◽  
NABEEL B. NABULSI ◽  
YIYUN HUANG ◽  
KEVAN C. HEROLD ◽  
...  

2007 ◽  
Author(s):  
Stefan Krüger ◽  
S. Pauls ◽  
Felix M. Mottaghy ◽  
Andreas K. Buck ◽  
Hubert Schelzig ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document